Source: AllCare Physio/ Facebook
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia (HLA) purchases two AllCare Physiotherapy stores and a John Holme Optometrist for $2.46 million
  • The company has also entered into an agreement to purchase Anytime Physio in Newstead, Queensland
  • The newly purchased business are expected to contribute a revenue of $3.95 million and EBITDA of $640,000
  • Managing Director, Wesley Coote, says the company’s vision is to build the leading allied health care business in the Australian market
  • On market close, Healthia was down 6.25 per cent, trading at $1.80 per share

Healthia (HLA) has agreed to purchase two AllCare Physiotherapy stores and a John Holme Optometrist for $2.46 million.

The physiotherapy clinics are located in Hobart, Tasmania, while the optometrist includes two stores in Northern Queensland.

The company has also entered into an agreement to purchase Anytime Physio in Newstead, Queensland.

The newly purchased businesses are expected to contribute a revenue of $3.95 million and earnings before interest, tax, depreciation and amortisation (EBITDA) of $640,000.

Managing Director, Wesley Coote, said the company’s vision is to build the leading allied health care business in the Australian market.

“Our key target sectors of Bodies and Minds, Feet and Ankles, and Eyes and Ears have a collective addressable market of $9.8 billion,” Mr Coote said.

“We have a proven management team and a clinician and patient first culture and are excited to have these businesses joining our growing allied health network.”

Since listing on the ASX in September 2018, Healthia has grown its portfolio of allied health businesses from 104 to 217. This marks a 109 per cent growth and the company will continue adding value to its portfolio of assets.

On market close, Healthia was down 6.25 per cent, trading at $1.80 per share.

HLA by the numbers
More From The Market Online
The Market Online Video

Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie

From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer…
Lung imaging concept

Biotech lung imaging darling 4DX Medical back at $2.20/sh on Miami U contract

4DX Medical has seen its price jump back to $2.20/sh, as its next-gen lung imaging scan…
Chuffed bloke

Race Oncology’s placement-at-a-premium rewarded as shares jump +8%

Race Oncology has completed its recent A$3.2M placement – something that shareholders on the HotCopper forums…

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…